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The goal of the present study was to determine ifthe expression ofmetallothionein isoform 3
(MT-3) might serve as a biomarker for human bladder cancer. To accomplish this goal, we
defined the localization and expression ofMT-3 protein and mRNA using fresh and archival
biopsyspecimensobtainedfrompatientsundergoingdifferentialdiagnosis foravariety ofbladder
disorders. We used immiunohistochemistry, immunoblot, and RT-PCR analysis to define the
localization and expression ofMT-3 protein and mRNA. Immunohistochemical analysis dis-
dosed no immunoreactivity for MT-3 in normal bladder cells. The absence ofMT-3 expression
in the normal bladder was firther confinned by demonstrating that MT-3 mRNA could not be
detected using reverse transcriptase-polymerase chain reaction (RT-PCR) or MT-3 protein using
immunoblot. Immunohistochemistry also disdosed no immunoreactivity for MT-3 in archival
biopsy specimens from patients with interstitial cystitis and related disorders.
Immunohistochemical analysis demonstrated that MT-3 was expressed in carcinoma in situ
(CIS), high-grade bladder cancer, low-grade bladder cancer, and dysplastic lesions. MT-3
immunostaining was intense in both CIS andhigh-grade bladder cancer, and low to moderate in
low-grade bladder cancer and dysplastic lesions. We determined MT-3 mRNA expression in a
subset of these bladder cancer specimens; expression was elevated as compared to that of the
housekeeping gne,I0-actin. ThecDNAfromthe RT-PCRreaction primedforMT-3 contained a
Fold restriction site, a site unique for MT-3 as compared to other MT family members. In con-
dusion, this studydemonstrates thatMT-3 isup-regulatedinhuman bladdercancerandthat this
up-regulation increases with increasingtmor grade. The finding that MT-3 expression is mini-
mal in normal bladder sugests that MT-3 might be developed into an effective biomarker for
bladder cancer. Keyworkr. biomarker, bladder, bladdercancer,carcinoma ins, cystitis, immuno-
histochenist, inflammation,interstitial cystids,mealiothionein, RT-PCR,transitionalcellcarci-
noma,urothelium. EnvironHealthPepec 108:413 418 (2000). [Online 17March20001
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The progress against bladder cancer over the
last 20 years and the current diagnosis and
treatment strategies for managing the disease
have been the subject ofrecent reviews (1,2).
In the United States over 54,000 new cases
of bladder cancer are diagnosed each year
and more than 12,000 annual deaths result
from the disease (3). Bladder cancer is the
fifth most common cancer in the United
States, and approximately 15-30% of blad-
der tumors showgrade and stage progression
(4). Metastasis is the main cause ofdeath in
bladder cancer patients, and approximately
50% of patients who present with muscle-
invasive bladder tumors die from metastatic
disease (5). The number of cases ofbladder
cancer has increased each year for the past 20
years while the mortality attributed to the
disease has remained relatively constant (1).
Epidemiologically, bladder cancer repre-
sents one of the first cancers in which envi-
ronmental carcinogens were found to play the
major role in causing the disease. In 1895,
Rehn (6) observed an association between
exposure to aromatic amines and bladder can-
cer in factory workers. This association was
confirmed in both animal models and in
humans working in industries that involved
exposure to aromatic amines (7,8). Many
studies have described an association between
cigarette smoking and bladder cancer; some
reports suggested a 2- to 4-fold increased risk
and that 50% ofthe bladder cancers in men
would not occur in the absence of cigarette
smoking (9,10). The majority ofthe remain-
ing bladder cancers are believed to be caused
by industrial or agricultural carcinogens. The
number of cigarettes smoked, degree of
inhalation, type oftobacco, use offilters, and
smoking cessation all have specific relation-
ships to the development of bladder cancer
(11). There are no widely accepted tumor
markers that allow widespread screening for
theearlypresence ofbladder cancer orfor the
detection and monitoring of advanced
metastatic disease; however, evidence suggests
that such markers could impact on reducing
the mortality of this disease [reviewed by
Lamm (1) and Droller (4].
The need for effective biomarkers for the
detection of bladder cancer led us to define
the expression of metallothionein isoform 3
(MT-3) in the normal and cancerous
bladder. The rationale for this examination
comes from recent findings showing that
MT-3 is expressed in the epithelial compo-
nents of both the normal kidney and
prostate gland, with altered expression in
organ-derived cancers (12-14). The finding
of MT-3 expression in these organs was
unexpected because the recentlycharacterized
MT-3 gene was initially reported to have a
highly restricted expression pattern confined
to neural tissues (15). The finding that MT-3
was expressed in other tissues ofthe urogeni-
tal system motivated the expansion of this
analysis to determine ifMT-3 is expressed in
the bladder, and if this expression is altered
in epithelial cell-derived cancers.
Materials and Methods
Bladdr specimensfor immunohistochemical
analysis ofMT-3 expression. For the
immunohistochemical analysis of MT-3
expression, we obtained biopsy tissues from
paraffin blocks that originated from previ-
ously completed patient diagnostic proce-
dures. These biopsy specimens are archived,
after completion ofdiagnostic procedures, in
the Department of Pathology of the West
Virginia University Hospitals (Morgantown,
WV). To define the immunohistochemical
expression of MT-3 in control and non-
cancerous lesions ofthe bladder, we utilized
a set of paraffin-embedded tissue samples
that had been used previously to determine
heat shock protein expression in the bladder
of patients with interstitial cystitis (IC) and
IC-like syndromes (16-18). This set ofsam-
ples consisted of 7 specimens of control,
nondiseased, adult bladder; 9 specimens
from six adult patients with a diagnosis of
cystitis; 1 1 specimens from nine adult
patients with a diagnosis ofIC; 6 specimens
from three adult patients with a possible
diagnosis ofIC; and 6 specimens from adult
patients with symptoms ofcystitis after suc-
cessful BCG (bacille Calmette-Gudrin)
therapy for transitional cell carcinoma
(TCC). The nine cases of cystitis displayed
varying degrees of inflammation, and three
of the cases met histopathologic criteria for
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follicular cystitis. In 10 of the adult speci-
mens, multiple biopsies from different areas
ofthe bladder were available. IC occurs pre-
dominantly in female patients and all IC
samples were from females.
We determined the immunohistochemi-
cal expression ofMT-3 in urothelial carcino-
ma of the bladder on paraffin-embedded
archival tissue samples from 20 patients with
a diagnosis of TCC of the bladder. These
patients (13 males and 7 females) had all
undergone treatment for bladder cancerwith
BCG therapy and most had undergone mul-
tiple bladder biopsies during the course of
treatment. The average age was 62.4 at the
time ofdiagnosis. At the time ofinitial diag-
nosis, 8 patients had biopsies demonstrating
low-grade urothelial carcinoma (LG TCC)
and 12 patients had high-grade urothelial
carcinoma (HG TCC), 11 ofwhich were
proven by biopsy and one ofwhich had pos-
itive cytology. The initial biopsies showed
carcinoma in situ (CIS) in one patient with
low-grade papillary urothelial carcinoma and
in three patients with HG TCC. None of
the patients demonstrated musde invasion at
the time of initial diagnosis; all were staged
at Ta (15), TI (4), or TIS (1). During the
course oftreatment, seven patients exhibited
only low-grade recurrences; four patients
had high-grade recurrences without histolog-
ically evident CIS; three patients had both
high-grade and low-grade recurrences; one
patient had low-grade papillary carcinoma
with adjacent areas of CIS; three patients
had high-grade carcinoma with areas ofCIS;
and one patient exhibited the full spectrum
ofurothelial cell carcinomas with sequential
biopsies demonstrating high-grade carcino-
ma, low grade carcinoma, and CIS. There
were a total of92 biopsies on these patients;
individual patients had between 1 and 20
biopsies in the course of treatment. From
these 92 biopsies, we selected 55 specimens
for immunohistochemical examination. For
analysis of MT-3 expression, we subdivided
the specimens into five categories. The
benign category consisted of33 observations
from patients with TCCs that were histolog-
ically benign. Eleven of these sections were
from patients who had other biopsies taken
at the same time that revealed either LG
TCC (five sections) or HG TCC (six sec-
tions) and 10 were from patients with TCC
whose biopsies were negative but who were
positive for TCC on other independent
examinations. Twelve observations ofbenign
urothelium came from sections with malig-
nancy (nine LG TCC and three HG TCC)
that had adjacent areas ofhistologically nor-
mal urothelium. The dysplasia included 18
observations from sections with malignancy
that had adjacent areas histologically defined
as being dysplastic using standard diagnostic
criteria. The LG TCC category consisted of
23 observations from 21 biopsies obtained
from 13 patients. The HG TCC category
contained lesions defined by standard diag-
nostic criteria as HG TCCwithout histolog-
ically demonstrable areas of CIS. In this
group, a total of 25 sections from 18 sepa-
rate biopsies from 12 patients were available.
The CIS category consisted ofseven sections
from six separate biopsies from six patients
with areas that met standard diagnostic crite-
ria for CIS. One biopsy demonstrated only
CIS; four had concomitant HG TCC, and
the remaining two had LG TCC. The
degree ofMT immunoreactivity was judged
by two pathologists using a 0 to +4 scale,
where 0 indicated negative immunoreactivi-
ty and +4 strong immunoreactivity. The
slides used in the analysis were blinded for
disease status by random numbering of the
slides and these were decoded onlyafterboth
pathologists had completed the evaluation of
staining intensity.
Bladder specimensfor analysis ofMT-3
mRNA expression. To determine the MT-3
mRNA expression in control bladder, we
used three independent samples of total
RNA prepared from undiseased adult blad-
der from the previous studies on IC (16-18)
and added three additional samples for the
present analysis. These total RNA samples
were prepared from six independent speci-
mens of undiseased adult bladder obtained
from biopsy or surgical specimens after the
completion ofdiagnostic protocols. For the
determination ofMT-3 mRNAexpression in
TCC, we isolated total RNA from full-thick-
ness (10 pm) sections from a subset of the
paraffin-embedded tissues to determine the
immunohistochemical expression ofMT-3 in
TCC. We chose samples where the malig-
nant lesion made up over 85% ofthe section.
Immunohistochemical localization of
MT-3. We generated the affinity purified
antibody against human MT-3 using the
dodecapeptide GGEAAEAEAEKC (corre-
sponding to MT-3 amino acids 53-64,
which contain the MT-3 unique amino acid
insert) conjugated through the C-terminal
cysteine SH group to keyhole limpet hemo-
cyanine using maleimidobenzoyl-N-hydrox-
ysuccinimide ester, as described previously
(13,14). This antibody was used to immu-
nize New Zealand white rabbits. The MT-3
antibody was affinity purified using the
dodecapeptide linked to SulfoLink gel
(Pierce, Rockford, IL) through the C-termi-
nal cysteine residue. Archival bladder speci-
mens were routinely fixed in 10% neutral
buffered formalin for 16-18 hr. All tissues
were transferred to 70% ethanol and dehy-
drated in 100% ethanol. Dehydrated tissues
were cleared in xylene, infiltrated, and
embedded in paraffin. We cut serial sections
at 3-5 pm for use in immunohistochemical
protocols. Before immunostaining, sections
were pretreated in a microwave at 700 W in
10 mM citrate buffer (pH 6.0) for 5 min.
The sections were allowed to cool for 5 min
at room temperature, then microwaved
again for 5 min and immersed into distilled
water. The affinity purified primary anti-
MT-3 antibody was localized using the
avidin-biotin-peroxidase complex (ABC)
procedure (BioGenex optimax immunos-
tainer; BioGenex, Inc., San Ramon, CA)
using diaminobenzidine for visualization
(stable DAB; Research Genetics, Huntsville,
AL). We rinsed the slides in distilled water,
dehydrated them in solutions containing
graded ethanol concentrations, cleared them
in xylene, then placed coverslips on them.
Thenegative controls consisted ofomissionof
primary antibody from the immunohisto-
chemical ABC sequence and abolishment of
staining by titration ofthe primary antibody
with the peptide used for immunization. The
positive control usedsectionsofhuman brain.
RNA isolation and RT-PCR analysis of
MT-3 mRNA expression in normal blUdder.
We ground bladder tissue to a powder under
liquid nitrogen and isolated total RNA from
the powdered tissue according to the protocol
supplied with TRI REAGENT (Molecular
Research Center, Inc., Cincinnati, OH), as
described previously (19,20). We determined
the concentration and purity of the RNA
samples using spectrophotometer scan in the
ultraviolet region and ethidium bromide
(EtBr) visualization of intact 18S and 28S
RNA bands after agarose gel electrophoresis.
Total RNA (0.5 pg) was reverse transcribed
using murine leukemia virus reverse tran-
scriptase (50 U) in 1 x polymerase chain
reaction (PCR) buffer (50 mM KCI and 10
mM Tris-HCl, pH 8.3), 5 mM MgCI2, 20
U RNase inhibitor, 1 mM each of the
dNTPs, and 2.5 1M random hexanucleotide
primers. The samples were reverse tran-
scribed for 20 min at 420C, followed by a 5-
min denaturation step at 99°C using a
GeneAmp 9600 thermocycler (Perkin Elmer
Applied Biosystems, Foster City, CA). We
utilized the reverse-transcribed product for
PCR amplification using the AmpliTaq
DNA polymerase enzyme (2.5 U) and the
specific upstream and downstream primers
at a concentration of0.1 pM each. All PCR
reagents were purchased from Perkin Elmer.
The thermocycler was programmed to cycle
at 95°C for a 2-min initial step, at 95°C for
30 sec, and at 68°C for 30 sec, with a final
elongation step at 68°C for 7 min. Negative
controls for each PCR included a no-tem-
plate control, wherewater was added instead
of the RNA, and a no-reverse transcriptase
control, where water was added instead of
the enzyme. Positive controls for MT-3
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expression used total RNA from prostate
and kidney, where MT-3 is expressed
(12-14). We removed samples at 25, 30, 35,
and 40 PCR cycles to ensure that the reac-
tion remained in the linear region. The final
PCR products were electrophoresed on 2%
agarose gels containing EtBr along with
DNAmarkers.
RNA isolation andRT-PCR analysis of
MT-3 mRNA expression in TCC using
paraffin-embedded tissue. Thick sections (10
pm) were cut from formalin-fixed, paraffin-
embedded tissue blocks with a microtome.
We trimmed the excess paraffin with a sterile
blade, then placed the tissue in a 1.5-mL
microfuge tube. The tissue was deparaffinized
twice at 55°C with xylene for 5 min followed
by two washes with 100% ethanol to remove
the xylene. We extracted RNA from the
deparaffinized tissue using the micro RNA
isolation kit (catalog no. 200344; Stratagene,
LaJolla, CA). We added 200 1L denaturing
buffer containing guanidine isothiocyanate
and 1.6 mL 3-mercaptoethanol to the sam-
ple and vortexed it vigorously. We added 20
pL 2 M sodium acetate (pH 4.0) solution to
the samples, along with 220 pL phenol and
60 1L chloroform:isoamyl alcohol. The
samples were vortexed and placed on ice for
15 min, followed by centrifugation at maxi-
mal speed in a microfuge for 30 min at 4°C
to separate the aqueous and organic phase.
We transferred the upper aqueous phase to a
fresh tube and added 1 pL glycogen (2
pg/jiL). RNAwas precipitatedwith the addi-
tion of 200 pL ice-cold isopropanol. The
samples were left overnight in a -70°C freez-
er after centrifugation at maximal speed in a
microfuge for 30 min at 4°C. The super-
natant was removed and the RNA pellet was
washed twice with 70% ethanol. The pellet
was dried on ice and resuspended in RNase
freewater.
Total RNA (1 pL) was reverse transcribed
in a 20-pL reaction mixture using murine
leukemia virus reverse transcriptase (50 U) in
1 x PCR buffer, 5 mM MgCI2, 20 U RNase
inhibitor, 1 mM each ofthe dNTPs, and 2.5
pM random hexanucleotide primers. The
sampleswere reverse transcribed for 20 min at
420C, followed by a 5-min denaturation step
at 99°C using the GeneAmp 9600 thermocy-
der. The resulting cDNA was amplified in a
100-pL reaction mixture containing 2 mM
MgCl2, 1 x PCR buffer, 2.5 U AmpliTaq
DNApolymerase, and 0.1 pM ofthe respec-
tive outer primers. We performed the PCR
for 30 cycles as follows: 95°C for 30 sec and
680C for 30 sec, followed by a 7-min final
extension step at 680C. Controls for each
PCR included a no-template control in
which 1 [iL water was added instead of the
RNA and a no-reverse transcriptase control
in which 1 1iL ofwater was added instead of
the enzyme. Five microliters of the product
from the first-round of PCR was added to
95 pL ofa PCR mixture (2 mM MgCl2, 1 x
PCR buffer, 200 pm dNTPs, 2.5 U
AmpliTaq DNA polymerase, and 0.1 pM of
the respective inner primers) for a second
round ofPCR. For MT-3, the samples were
removed at 18, 20, and 22 cycles, whereas
the samples were removed at 30, 35, and 40
PCR cycles for P-actin. We developed the
outer and inner nested primers forhuman ,B-
actin gene and MT-3 using Oligo 5.0 soft-
ware (Molecular Biology Insights Inc.,
Cascade, CO). To maintain the MT isoform
specificity, the lower outer- and inner-
primer sequence for MT-3 was the same
according to the Oligo primer analysis pro-
gram. The sequences of the outer and inner
nested primers alongwith theproduct sizes for
,-actin were as follows: outer primer upper 5'
ATGGATGATGATATCGCCGCG 3' and
lower 5' CTCCATGTCGTCCCAGTTG-
GT 3' (product size: 249 bp), and nested
inner primer upper 5' CGACAACGGCTC-
CGGCATGT 3' and lower 5' TGCCGT-
GCTCGATGGGGTACT 3' (product size:
194 bp). The sequences for MT-3 were as
follows: outer primer upper 5' CCGTTCAC-
CGCCTCCAG 3' and lower 5'CACCAGC-
CACACTF'lCACCACA 3' (product size: 325
bp), and nested inner primer, upper 5'
TCGACATGGACCCTGAGACCT 3' and
lower 5' CACCAGCCACACTTFCACCACA
3' (product size: 296 bp). The final PCR
products were electrophoresed on a 2%
agarose gel containing EtBr alongwith DNA
markers (Gibco BRL, Grand Island, NY) to
verify the size of PCR products. We deter-
mined the intensity (integrated optical
density) of the PCR product bands on a
Roche Pathology workstation (Autocyte,
Burlington, NC) configured with Kontron
KS 400 (Zeiss, Thornwood, NY) image
analysis software.
Specific cleavage of the MT-3 reaction
product used the FokI restriction enzyme.
After reverse transcriptase (RT)-PCR (100
jiL reaction volume), reaction products were
purified using the QiaQuik PCR Purifi-
cation system (Qiagen, Inc., Valencia, CA)
according to the manufacturer's recom-
mended protocol. DNA was eluted into 30
pL TE buffer (10 mM Tris, pH 8.0, 1 mM
EDTA). The FokI restriction digestion of
MT-3 was carried out by adding NE4
Buffer (New England Biolabs, Beverly,
MA), dH2O, and 10 U FokI enzyme (New
England Biolabs) in a final reaction volume
of 50 jL to the eluted DNA samples. After
incubation at 37°C for 1 hr, we terminated
the reaction by. adding 5 pL gel-loading
buffer. The samples were electrophoresed
on a 2% TBE-agarose gel containing 0.5
jig/mL EtBr.
MT-3 protein determination. Bladder
tissue samples were homogenized in sodium
dodecyl sulfate (SDS) buffer (50 mM Tris,
pH 6.8; 2% w/v SDS). Aliquots of 60 pg
protein were diluted to 100 pL with buffer
consisting of 0.2 M Tris (pH 8.8) and 0.2
M dithiothreitol and heated at 650C for 15
min to reduce any partially oxidized protein.
The samples were centrifuged through a 10-
kD molecular weight cutoffcentrifuge filter
(Micron Separations, Westboro, MA).
Volumes offiltrate representing 6 pg protein
were diluted to 75 pL with PBS and mixed
with an equal volume of3% glutaraldehyde
to enhance detection of MT-3. We applied
100 pL of this mixture (2 pg total protein)
to a dot-blot apparatus with a polyvinylidine
difluoride membrane. Samples were allowed
to flow through the apparatus by gravity,
then washed 2 times with PBS. After block-
ing with 3% bovine serum albumin in PBS,
the membrane was soaked in primary anti-
body (4.5 pg/mL, 1% BSA in PBS) for 2 hr.
We washed the membrane 3 times with
PBS, and we added alkaline phosphatase-
conjugated secondary antibody (Promega,
Madison, WI) at a 1:500 dilution. Antibody
complexes were visualized using the alkaline
phosphatase kit III (Vector Laboratories
Inc., Burlingame, CA). We applied standard
curves of the conjugated synthetic peptide
(Sigma Chemical Co., St. Louis, MO) to
each blot. MT-3 protein was quantified by
comparing the optical density ofthe sample
dots to the standard MT-3 curve using KS
400 image analysis software. This assay has
detection limits in the range of0.5-2.0 pg
MT-3 protein.
Results
Localization and expression ofMT-3 in the
bladerfrom controls andpatients with IC
and related disorders. In previous studies,
the human kidney has been shown to be
immunoreactive for MT-3 protein and to
express both MT-3 mRNA and protein by
RT-PCR and Western analysis (12,13). For
the immunohistochemical analysis ofMT-3
expression in the normal bladder, we includ-
ed sections of human kidney as a positive
control during each automated immunohis-
tochemical sequence (Figure 1A). The indu-
sion of a positive control within each run
was especially important in this instance
because none ofthe cell types present in the
samples of normal control bladder demon-
strated convincing immunoreactivity for
MT-3 under identical conditions ofanalysis
(Figure iB). As compared to a negative con-
trol, where MT-3 antibodywas deleted from
the reaction sequence, MT-3 immunoreac-
tivity in the normal bladder was only nomi-
nally, ifat all, above background levels (data
not shown). This finding is one indication
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that the normal human bladder has a very
low expression of MT-3. To further define
the level ofexpression ofMT-3 in the nor-
mal bladder, we isolated total RNA and pro-
tein from six samples of control bladder
(four females and two males). We used the
isolated RNAand proteins to determine the
expression of MT-3 mRNA and protein,
respectively. The expression of MT-3
mRNA was not detected in any of the six
control bladder samples at 35 cycles ofnon-
nested RT-PCR and total RNA inputs of
0.5 pg (Figure 2). These identical total RNA
samples yielded strong reaction products for
the housekeeping gene, P-actin, at 35 reac-
tion cycles and equal total RNA inputs. As
an additional control, we also obtained
strong reaction products for MT-3 mRNA
from total RNAsamples from human kidney
at 35 cycles and equal total RNA inputs
(Figure 2). Extension ofthe RT-PCR to 40
cycles failed to produce reaction product for
MT-3 in five ofthe six bladder samples and
only a very faint reaction product band was
evident in the remaining bladder sample
(data not shown). An analysis ofMT-3 pro-
tein byimmunoblot failed to detect the pres-
ence of MT-3 protein in any of the six
preparations (data not shown). The limit of
detection of the assay is approximately 0.5
pg/pg protein. Thus, the analysis of MT-3
expression using total RNA and protein
from the human bladder reinforced the
immunohistochemical findings regarding
MT-3 expression in the normal bladder.
A variety of other nonmalignant disor-
ders ofthe human bladder that are normally
diagnosed by tissue biopsy were examined
.........
for the immunoreactivity of MT-3. These
induded biopsy samples from patients with
cystitis, with IC meeting the National
Institutes of Health (NIH) research criteria
for this disease entity, with symptoms ofIC
that did not meet all of the NIH criteria,
and with symptoms ofcystitis after success-
ful BCG therapy for TCC. In all instances,
no immunoreactivity for MT-3 was demon-
strated in any ofthe cell types in the bladder
(data notshown).
Localization andexpression ofMT-3 in
the bladderfrom patients with transitional
cellcarcinoma. In contrast to control urothe-
lium, MT-3 immunoreactivity was demon-
strated in LG TCC (Figure IC), HG TCC
(Figure 1D), and in CIS (Figure 1E) of the
human bladder. The majorityofMT-3 stain-
ing within tumors was cytoplasmic. Some
tumors, both LG TCCs and HG TCCs, also
demonstrated strong nuclear localization
(Figure IF). Several ofthe samples from each
tumor grade also had areas of dysplasia in
addition to the carcinoma. In general,
although the intensity ofMT-3 immunore-
activity within the dysplastic regions was less
than that of the corresponding malignant
lesion, there were examples within each
tumor grade where the staining was ofmod-
erate intensity. The MT-3 immunostaining
within these dysplastic areas appeared elevat-
ed over that ofnormal urothelium (data not
shown). Although present in only a few sam-
ples, there was also a tendency forweak MT-
3 immunoreactivitywithin Brunn's nests and
in areasofcystitis cystica.
In all cases, MT-3 immunoreactivity was
diffuse and was localized to the cytoplasm of
the cells and, although variable in intensity
among the tumor specimens, all malignant
lesions appeared to be immunoreactive for
MT-3, albeit a few low-grade lesions only
weakly. When the qualitative visual obser-
vation ofMT-3 immunoreactivity was blind-
ed and quantified as a function of tumor
grade, the intensity ofMT-3 immunostaining
increased as a function oftumor grade (Table
1). When we examined the immunostaining
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Figure 1. Immunohistochemical analysis of MT-3 expression. (A) MT-3 demonstrates heterogeneous
staining ofthe renal tubules, including strong immunoreactivity ofthe distal tubules. MT-3 dilution (1:100);
no counterstain; 200 x magnification. (B) Normal urothelium demonstrates negative or very weak
immunoreactivityto MT-3. MT-3 dilution (1:100); no counterstain; 200 x magnification. (C) LG TCC demon-
strates weak to moderate immunoreactivity with MT-3. Similar staining was seen for both invasive and
papillary disease. MT-3 dilution (1:100); no counterstain; 200 x magnification. (D) HG TCC demonstrates
moderate to strong immunoreactivity to MT-3. Similar staining was seen for both invasive and papillary
disease. MT-3 dilution (1:100); no counterstain; 200 x magnification. (E) CIS ofthe urinary bladder demon-
strates strong immunoreactivity to MT-3. MT-3 dilution (1:100); no counterstain; 200 x magnification. (F)
Nuclear localization was observed in some urothelial carcinomas. This low-grade papillary urothelial car-
cinoma demonstrates strong nuclear localization with weak to moderate cytoplasmic immunostaining to
MT-3. MT-3 dilution (1:100); no counterstain; 200 x magnification.
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Figure 2. Expression of MT-3 mRNA in control
bladder. RT-PCR for P-actin (lane a) and MT-3
(lane b) was performed on two kidneytissue sam-
ples (2 and 9) and six control bladder samples
(3-8). Lanes 1 and 10 are DNA base pair ladders.
The total RNA input was 0.5 pg and the reaction
products were removed at35 cycles.
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results for the biologic classes, benign
urothelium, dysplastic urothelium, LG-
TCC, HG-TCC, and CIS using the
Kolmogorov-Smirnov one-sample test and
Systat software (SPSS, Inc., Chicago, IL), we
found significant differences between all
groups (two-sided probability > 0.003).
Thus, increased MT-3 immunoreactivity
and the malignant phenotype demonstrated
a consistent positive correlation in the
human bladder.
We determined the expression ofMT-3
mRNAby nested RT-PCR in asubset ofthe
samples used for the determination ofMT-3
immunoreactivity. We evaluated these full-
thickness sections of paraffin-embedded tis-
sue by microscopic examination, and we
selected those where the malignant lesion
made up > 85% of the tissue sample. This
restriction allowed total RNA to be prepared
from 16 LG TCCs, 15 HG TCCs, and 5
CISs. In all cases, RT-PCR analysis resulted
in a reaction product of the expected num-
ber ofbase pairs (an example for each tumor
grade shown in Figure 3). Each sample also
expressed P~-actin mRNA, a housekeeping
gene commonly utilized to control for total
RNA integrity and to make comparisons of
gene expression patterns by comparison of
relative optical densities. In addition, the
MT-3 reaction product contains a FokI
restriction site not present in any other MT
gene. An RT-PCRproduct from each tumor
grade was subject to restriction cutting by
FokI and in each case we obtained cleavage
products ofthe expected size (e.g., Figure 4).
Together, these findings provide supporting
evidence that the MT-3 antibody detects
MT-3 protein expression in human bladder
cancer. The results also demonstrated that
the relative expression ofthe MT-3 reaction
product was greater than that ofthe 1-actin
housekeeping gene (Table 2). This is based
on the relative comparison ofthe integrated
optical densities of the 1B-actin and MT-3
reaction products. For the 36 samples of
bladder cancer, the intensity of the MT-3
RT-PCR product bands was approximately
60% of that of the P-actin housekeeping
gene (Table 2). We analyzed the MT-3 reac-
tion products after 22 cycles of nested RT-
PCR and we analyzed the ,B-actin after 35
cycles; this indicates a greater expression of
Table 1. MT-3immunoreactivity in bladder cancer.
Mean
Histologic staining
classification No. intensity SE Min Max
Benign 33 0.58 0.06 0.0 2.0
Dysplasia 18 0.92 0.13 0.5 2.5
Lowgrade 23 1.29 0.14 0.5 2.5
High grade 25 2.07 0.23 0.25 4.0
CIS 7 2.43 0.30 2.0 4.0
MT-3 mRNA as compared to that of 3-
actin. This comparison also disclosed that
the relative MT-3 mRNA levels were not
altered as a function oftumor grade, with all
grades having equal relative expressions.
Discussion
This study demonstrates that MT-3 is up-
regulated in human bladder cancer and that
up-regulation increases with increasing
tumor grade. However, a mechanistic
hypothesis to explain MT-3 overexpression
in bladder cancer cannot be proposed
because of the limited knowledge regarding
the MT-3 member of the MT gene family.
The MTs are a family ofcysteine-rich, low-
molecular-weight, intracellular proteins that
bind transition metals (21). In both mice
and humans, there are four classes ofsimilar
MT proteins, designated MT-1 through
MT-4, defined on the basis of small differ-
ences in sequence and charge characteristics
(21-23). The MT-1 and MT-2 isoforms
have been extensively studied and are
believed to serve an important role in the
homeostasis ofessential metals such as Zn2+
and Cu2+ during growth and development as
well as in the detoxification ofheavy metals
such as Cd2+ and Hg2+, rendering the MTs
important mediators and attenuators of
heavy metal-induced toxicity, particularly
hepato- and nephrotoxicity (21-25). The
MT-1 and MT-2 isoforms exhibit a ubiqui-
tous pattern of tissue expression and are
highly inducible by a number of stimuli
(21-24). In contrast, the MT-3 isoform has
been the subject ofonly limited study. The
gene for the MT-3 protein was isolated in
1992; preliminary studies suggested that its
expression was limited to neural tissues and
that the gene was not metal responsive (26).
The MT-3 isoform also possesses a unique
sequence ofeight amino acids that is not pre-
sent in any other member of the MT gene
family (26-28). Furthermore, in the neural
system and derived cell cultures, MT-3
LGTCC HG TCC CIS
500 bp
300bp
200 bp
100 bp:
50bp
Figure 3. MT-3 expression in bladder cancer.
Nested RT-PCR was performed on total RNA iso-
lated from LG TCC, HG TCC, and CIS. Bands repre-
senting PCR products for 1B-actin (194 bp) and
MT-3 (296 bp) obtained for each type of carcinoma
are shown. Lanes 1 and 10 are DNA ladders.
possesses a neuronal cell growth inhibitory
activity that is not duplicated by the other
human MT classes (27,29). This nondupli-
cation offunction occurs despite a 63-69%
homology in amino acid sequence among
MT-3 and the other human MT isoforms.
In the neural system, the N-terminal region
(and not the C-terminal sequence of eight
unique amino acids) ofMT-3 appears to be
necessary for its bioactivityand MT-3 bioac-
tivity is not related to metal-binding ability
(30). The finding that the neuronal expres-
sion of MT-3 is associated with the regula-
tion ofcell growth allows us to hypothesize
that the overexpression of MT-3 in human
bladder cancer might also influence the
regulation of urothelial cell proliferation.
Evidence that the regulation of MT-3
expression in bladder cancer will be complex
is suggested by the observation that the levels
of MT-3 mRNA and protein expression do
not have a direct correlation among the
tumorgrades. Although there is a progressive
increase in MT-3 protein as a function of
tumorgrade as determined by immunostain-
ing, the level ofMT-3 mRNA as determined
byRT-PCRremains equal across grades.
The rationale for proposing that MT-3
expression might serve as a biomarker for
human bladder cancer is supported by sever-
al observations in the present study. First, we
found that expression of MT-3 was unde-
tectable using immunohistochemical, west-
ern, and RT-PCR techniques in the normal
urothelium. MT-3 was also undetectable
immunohistochemically in biopsies from
other nonmalignant lesions of the bladder,
some ofwhich are characterized by increased
inflammation. These findings suggest that
MT-3 might have the minimal background
expression in normal tissue that is necessary
for a biomarker thatwould monitor the effect
of agents initiating and promoting the devel-
opment ofbladder cancer. Second, although
MT-3 immunoreactivity was increased in all
of the bladder cancers examined, the
2 3
500 bp
3o0 bp
200 bp
100 bp
Figure 4. Fold cleavage of nested MT-3 RT-PCR
product from total RNA derived from a section of
paraffin-embedded bladder cancer. Lane 1, DNA
base pair ladder; lane 2, undigested product (296
bp); lane 3, digested product(222 and 74 bp).
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Table2 MT-3 mRNA expression in bladder cancer.
Relative IOD
Histologic IODI-actina IOD MT-3b MT-3/,-actin ratio
classification Mean ± SE Min-max Mean ± SE Min-max mean ± SE
lowgrade, n= 16 14,204 ±736 8,366-17,746 8,799 ± 1,070 3,212-19,720 0.64 ± 0.08
High grade, n= 15 13,597 ± 173 6,902-16,784 7,487 ± 746 3,705-12,825 0.57 ± 0.06
CIS, n=5 13,559± 1,883 6,902-17,030 7,758 ± 1,635 4,322-13,858 0.63 ± 0.16
Abbreviations: IOD,integrated optical density; max,maximum; min, minimum.
f3-Actin at35cycles ofnested RT-PCR. MT-3at22cyclesofnested RT-PCR.
immunoreactivity was greatest in CIS. This
is important because improvements in the
treatment ofsuperficial bladder cancer have
had agreat impact on disease progression. As
reviewed by Lamm (1), BCG immunothera-
py has radically changed the management of
CIS. Before 1983, 54% ofpatients with CIS
developed muscle-invasive disease within 5
years. However, with the advent of BCG
therapy, 70% or more patients had a com-
plete response, and 65% ofcomplete respon-
ders remained disease free for 5 years. With
improved BCG maintenance schedules,
these numbers are now at 83 and 80%,
respectively. Unlike other cancers, CIS of
the bladder is a highly malignant, aggressive
neoplasm. Thus, a biomarker to detect blad-
der cancer in its earliest stage, when the
lesion is still superficial, has the potential to
have a large impact on preventing disease
progression. Lastly, the characteristics of
both the MT-3 protein and the MT-3 gene
sequence are amenable to the development
ofprobes for assays that could be utilized on
the urine or bladderwashings from individu-
als potentially exposed to environmental or
occupational agents that are bladder carcino-
gens. The eight-amino-acid sequence used to
raise the present antibody is unique among
the members of the MT gene family and,
based on the current results, appears to have
good antigenicity for raising an antibody of
high titer and specificity. Thiswould be nec-
essary to extend the current finding to the
development ofan immunoassay for MT-3
that could be used in large-scale screening
protocols. This unique sequence should also
allow the generation ofmonodonal antibod-
ies against the MT-3 protein. The sequence
of the MT-3 gene also has sufficient
sequence divergence in the 5' and 3'
untranslated regions to develop specific
primers for the RT-PCR analysis of MT-3
mRNA. Although probably not applicable to
large-scale screening protocols, such reagents
could be useful in monitoring for the pres-
ence of malignant cells in bladder washings
from individuals with adisease history.
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